July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Neuroprotective effects of topical neurotrophic factors applied individually or in combination on retinal ganglion cells of rats after optic nerve crush
Author Affiliations & Notes
  • Yuta Kitamura
    Ophthalmology, Chiba University, Chiba, CHIBA, Japan
  • Toshiyuki Oshitari
    Ophthalmology, Chiba University, Chiba, CHIBA, Japan
  • Guzel Bikbova
    Ophthalmology, Chiba University, Chiba, CHIBA, Japan
  • Takayuki Baba
    Ophthalmology, Chiba University, Chiba, CHIBA, Japan
  • Shuichi Yamamoto
    Ophthalmology, Chiba University, Chiba, CHIBA, Japan
  • Footnotes
    Commercial Relationships   Yuta Kitamura, None; Toshiyuki Oshitari, None; Guzel Bikbova, None; Takayuki Baba, None; Shuichi Yamamoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2487. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuta Kitamura, Toshiyuki Oshitari, Guzel Bikbova, Takayuki Baba, Shuichi Yamamoto; Neuroprotective effects of topical neurotrophic factors applied individually or in combination on retinal ganglion cells of rats after optic nerve crush. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2487.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the neuroprotective effects of three neurotrophic factors administered topically on retinal ganglion cells (RGCs) of rats following optic nerve crush.

Methods : Thirty-six Sprague-Dawley rats were divided into 6 groups with 6 rats/group. Rats were treated with topical 100 mM TUDCA, 100 mM citicoline, 10 ng/ml NT-4, combined TUDCA-citicoline (Doublet), or combined TUDCA-citicoline-NT-4 (Triplet). After 2 weeks, the number of surviving RGCs was determined by Brn3a immunostaining of retinal flat mounts. The adverse events after the topical administration were also recorded.

Results : Without any treatment, the density of RGCs was 4.64±7.31/mm2 at 2 weeks after the optic nerve crush which was significantly fewer than the 1857±334.7/mm2 in the normal control retinas (P <0.0001). The density of RGCs in the TUDCA-treated eyes was 678.4±144.6/mm2, in citicoline-treated eyes was 701.1±356.7/mm2, in NT-4-treated eyes was 70.4±29.8/mm2, in Doublet-treated eyes was 790±434.6/mm2, and in the Triplet-treated eyes was 795±563.6/mm2. The density of RGCs in all of the eyes that had received the different neurotropic agents was significantly higher than that of RGCs without treatment (P <0.0001). While the density of the RGCs in NT-4 treated eyes was lower than in the other treated groups, the density of RGCs among the other groups was not significantly different. The only adverse event was neovascularizations of the cornea, iris, and dilatation of the choroid vessels in 8 of 13 rats (62%) in the Doublet treated eyes.

Conclusions : Optic nerve crush causes a loss of RGCs and topical application of three neurotrophic factors individually or in combination protected the RGCs from death. Although the combination of neuroprotective agents has been shown to be effective in vivo, we should be aware of complications such as neovascularizations can occur in vivo. Further studies to identify the cause of adverse effects need to be performed.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×